Bliss GVS Pharma Subsidiary Secures UK MHRA Approval for Mesalazine Suppositories
Bliss GVS Pharma Ltd 路 Others (Uncategorized) 路 04 Nov 2026, 10:39 pm
Bliss GVS Pharma Subsidiary Secures UK MHRA Approval for Mesalazine Suppositories Bliss GVS Pharma Limited announced on 4th Nov'26 that its wholly owned UK subsidiary, Asterisk Lifesciences Ltd, has secured marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA), UK. The regulatory approval covers Mesalazine 1g Suppositories, strengthening the company's product portfolio and market reach in the UK pharmaceutical segment.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. 路 06 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 29 Oct 2026
